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Occult hepatitis B virus (HBV) infection is defined as the detection of HBV deoxyribonucleic acid (DNA) in the serum or liver
tissue of individuals who test negative for hepatitis B surface antigen (HBsAg). We undertook a prospective study to evaluate
the significance and course of occult HBV in patients with hepatitis C virus (HCV) cirrhosis undergoing orthotopic liver
transplantation (OLT). A sensitive real-time polymerase chain reaction assay was utilized to test for serum HBV DNA at
enrollment and for hepatic HBV DNA within the explant liver. Patients were followed with serum HBsAg and HBV DNA
post-OLT. A total of 56 patients with HCV cirrhosis were enrolled between October 2002 and July 2004; of these, 44 underwent
OLT. The overall prevalence of occult HBV based on positive serum HBV DNA was 16 of 56 (28%), and based on positive
hepatic HBV DNA (“occult HBV liver”) was 22 of 44 (50%). The presence of serum hepatitis B core antibody (anti-HBc) and
a past history of injection drug use correlated with occult HBV. Explant-proven hepatocellular carcinoma (HCC) was found in
13 of 22 (59%) patients with occult HBV liver compared to 8 of 22 (36%) patients without occult HBV liver (P  0.04, odds
ratio  3.1; confidence interval  2.1-5.4). Post-OLT, no cases of HBV reactivation were noted, and there was no significant
association between occult HBV and recurrent HCV. In conclusion, occult HBV is far more prevalent in patients with end-stage
HCV than would be expected from its prevalence in the general population. Occult HBV infection is strongly associated with
the presence of anti-HBc, history of injection drug use, and explant-proven HCC. Liver Transpl 14:534-540, 2008.
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Sensitive molecular techniques have revealed the per-
sistence of hepatitis B virus (HBV) genomes for decades
after recovery from self-limited acute HBV.1 This sero-
logically undetectable or “occult” infection is defined as
the detection of HBV deoxyribonucleic acid (DNA) in the
serum or liver tissue of individuals who test negative for
hepatitis B surface antigen (HBsAg).2,3 The clinical sig-
nificance of occult HBV infection is still being defined in
terms of its transmissibility, propensity for reactivation,
and progression to chronic liver disease. Transmission
of HBV from organ and blood donors positive only for
the hepatitis B core antibody (anti-HBc) has been
shown to result in a de novo hepatitis that is indistin-
guishable from overt infection.4,5 In addition, the
development of an immunosuppressed state due to
chemotherapy,6 organ transplantation,5 or human im-
munodeficiency virus7 infection has been shown to in-
duce viral reactivation in patients with occult HBV, with
Abbreviations: HBV, hepatitis B virus; DNA, deoxyribonucleic acid; HBV DNA, hepatitis B viral DNA; HBsAg, hepatitis B surface
antigen; HCV, hepatitis C virus; OLT, orthotopic liver transplantation; anti-HBc, hepatitis B core antibody; HCC, hepatocellular
carcinoma; RNA, ribonucleic acid; anti-HBs, hepatitis B surface antibody; ACR, acute cellular rejection.
Supported by an American College of Gastroenterology Career Development Award (02/12; 2002-2004 to K.S.).
Address reprint requests to Kirti Shetty, MD, Georgetown University Hospital, 2 Main, 3800 Reservoir Road, Washington, DC 20007. Telephone:
202-444-3700; FAX: 202-444-7304; E-mail: kirti.shetty@medstar.net
DOI 10.1002/lt.21284
Published online in Wiley InterScience (www.interscience.wiley.com).
LIVER TRANSPLANTATION 14:534-540, 2008
© 2008 American Association for the Study of Liver Diseases.
appearance of the typical serological profile seen in
overt HBV infection.
The significance of occult HBV following orthotopic
liver transplantation (OLT) is incompletely understood.
An earlier report by Chazouilleres et al.8 described the
presence of HBV DNA in the serum of 20 HBsAg nega-
tive post-OLT patients, attributed to occult pretrans-
plant infection in 5 individuals. Even though the result-
ant clinical course of affected patients was mild, this
study highlighted the concept of reactivation of occult
HBV infection. In addition to the direct effects of immu-
nosuppression, the HBV genome has been shown to
contain a steroid-responsive DNA sequence that, when
stimulated, results in an increase of HBsAg synthesis
and HBV gene reactivation.9
Cacciola et al.10 have offered important insights into
the clinical significance of occult HBV in the nontrans-
plant setting. Their analysis demonstrated that 33% of
those with hepatitis C virus (HCV) infection had evi-
dence of occult HBV infection, compared to 14% of
non-HCV infected controls. Among HCV-infected indi-
viduals, those with occult HBV were more likely to have
cirrhosis than those without detectable HBV se-
quences. These data suggest that occult HBV not only
exists at a higher prevalence in those with HCV, but
also appears to accelerate its progression.
We therefore undertook this study with 3 specific
aims: first, to determine the prevalence of occult HBV in
a transplant population with HCV cirrhosis; second, to
examine its course post-OLT, i.e., the risk of HBV reac-
tivation in the presence of immunosuppression; and
finally, to assess the effect, if any, of occult HBV on the
histological recurrence rate of post-OLT HCV.
PATIENTS AND METHODS
Patient Enrollment
Patients were prospectively enrolled from the inpatient
and outpatient liver transplantation services at the
Hospital of the University of Pennsylvania, Philadel-
phia, PA, USA. The enrollment period was from October
2002 to July 2004. All patients had detectable serum
HCV viral ribonucleic acid (RNA). Each individual had
undergone a detailed medical and surgical evaluation
and had been placed on the United Network for Organ
Sharing waiting list for OLT. Exclusion criteria included
the presence of HBsAg, human immunodeficiency virus
antibody positivity, use of immunosuppressant medi-
cations prior to OLT, prior organ transplant status,
acute liver failure, living donor liver transplantation,
and use of an anti-HBc positive graft. At the time of
enrollment into the study, patients underwent labo-
ratory testing, which included a complete blood
count, liver panel, prothrombin time, HBsAg, anti-
HBc, hepatitis B surface antibody (anti-HBs), HCV
antibody, quantitative HCV RNA, and HCV genotype.
Serum was collected at enrollment for HBV DNA anal-
ysis. At the time of OLT, liver tissue was obtained
from the explant, snap-frozen, and HBV DNA analysis
was performed. The protocol was approved by the
Institutional Review Board at the University of Penn-
sylvania.
Patient Follow-Up
Post-OLT hospital visits occurred as per a standard
clinical protocol. At 8 and 24 weeks following OLT,
quantitative HCV RNA, HBsAg, and serum HBV DNA
analyses were done. Liver biopsies were performed in
the presence of abnormal liver-associated enzymes,
and were interpreted by 2 experienced hepatopatholo-
gists. Recurrent hepatitis C was defined on the basis of
microvascular/macrovascular steatosis, lymphoid ag-
gregates, and bile ductular changes.11 The diagnosis of
fibrosing cholestatic hepatitis was made based on pre-
viously published criteria.12 All liver biopsy samples
underwent immunohistochemical staining for HBsAg
and hepatitis B core antigen.
The immunosuppression protocol consisted of a ste-
roid taper over 3 months. Tacrolimus was the mainstay
of immunosuppression with the goal of target trough
levels in the first year between 8 and 12 ng/mL. To
minimize tacrolimus exposure, mycophenolate mofetil
was used in selected patients with renal insufficiency.
In 4 patients transplanted in 2003 and 2004, rapamy-
cin was substituted for tacrolimus, for renal insuffi-
ciency presumed to be related to tacrolimus at a median
post-OLT follow-up of 7 months.
A total of 12 patients did not undergo OLT, and were
not subjected to explant analysis. The true prevalence
of occult HBV in these patients could not be accurately
assessed. Hence, for the purpose of all comparative
analyses, only transplanted patients were included,
i.e., 22 patients with positive liver HBV DNA (“occult
HBV liver”) were compared to 22 patients without evi-
dence of HBV DNA in liver tissue.
None of the patients received oral HBV therapy or
prophylaxis after determining the presence of occult
HBV.
HCV RNA Analysis
Serum HCV RNA was detected and genotyped with
commercially available assays (COBAS Amplicor HCV;
Roche Molecular Diagnostics, Branchburg, NJ and
INNO-LIPA HCV II; Innogenetics, Gent, Belgium, re-
spectively). Serum HCV RNA quantification was per-
formed at the time of enrollment and post-OLT using
the branched DNA technique, and results were ex-
pressed as International Units (IU/mL, Versant 3.0;
Bayer Diagnostics, Tarrytown, NY, detection threshold
615 IU/mL).
HBV DNA Analysis
All HBV DNA analyses were done at the University of
Michigan laboratories (by M.H. and A.L.).
Quantification of Serum HBV DNA
HBV DNA was extracted from 200 L of serum using
the QIAamp DNA blood minikit (Qiagen,Valencia, CA)
and quantified in a real-time polymerase chain reaction
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assay as described previously.13 The lower limit of de-
tection of this assay is 25 copies/mL and the dynamic
range is 1.4 to 10.0 log10 copies/mL.
Quantification of Intrahepatic HBV DNA
HBV DNA was extracted from 25 mg of liver explants
using the QIAamp DNA minikit (Qiagen) and total HBV
DNA was quantified in a real-time polymerase chain
reaction assay, as described previously.14 The lower
limit of detection of this assay is 1  106 copies/cell
and the dynamic range is 6 to 2 log10 copies/cell. To
monitor for contamination during each step, sterile
double-distilled water and liver specimens from unin-
fected patients (HBsAg and anti-HBc negative with un-
detectable HBV DNA in serum by polymerase chain
reaction assay) were used as negative controls. Quan-
tification of -Actin was used to estimate the amount of
genomic DNA in each liver sample.
Statistical Analysis
Student’s t-test and Mann-Whitney test were used to
analyze quantitative data. Fisher’s exact test was used
to analyze qualitative data and for comparing propor-
tions. All P values were 2-tailed, a P value 0.05 was
considered to indicate statistical significance. Survival
analyses were done utilizing Kaplan-Meier methods.
Multivariate regression analysis was used to assess
risk factors for occult HBV liver, as well as for hepa-
tocellular carcinoma (HCC), utilizing age, gender, se-




A total of 56 patients were enrolled into this study; 3
patients died prior to OLT, and thus only had enroll-
ment serum available for analysis. A total of 9 patients
had not undergone OLT at the time of study closure. Of
the enrolled patients, 49 (88%) were male, and 42 (75%)
were Caucasian. The mean age at enrollment was 51.9
yr. The mean Model for End-Stage Liver Disease score
at enrollment was 17.2 and at OLT was 20.1. The ma-
jority of patients (71%) had HCV genotype 1 infection.
Two-thirds (66%) of the patients had a history of alcohol
abuse, 66% had a past history of intravenous drug
abuse.
Prevalence of Occult HBV (Fig. 1)
Serum Analysis at Enrollment (Pre-OLT)
A total of 16 of 56 (28%) patients had detectable serum
HBV DNA at enrollment with concentrations varying
from 1.7 to 2.3 log10 copies/mL (median 2 log10 copies/
mL). Of these patients, 13 underwent OLT, 2 were
awaiting OLT at the time of study closure, and the
remaining patient died prior to OLT.
Explant Liver Analysis
A total of 22 of 44 (50%) patients had detectable HBV
DNA in their explant liver with concentrations ranging
from 0.12 to 4.9 log10 copies/cell (median 2.8
log10 copies/cell). They included all 13 patients with
detectable serum HBV DNA at enrollment that under-
went OLT and an additional 9 patients who had unde-
tectable serum HBV DNA at enrollment.
Thus, in total, 25 of the 56 patients enrolled (45%)
tested positive for HBV DNA in serum and/or liver.
Risk Factors for Occult HBV Liver (Table 1)
A total of 22 patients with detectable HBV DNA in the
explant liver (designated as having occult HBV liver)
were compared to 22 patients without hepatic HBV
DNA. On univariate analysis, significant differences
were noted between the two groups in terms of MELD
score at entry, anti-HBc status, past intravenous drug
abuse and explant-proven HCC. No significant differ-
ences were noted in terms of age, gender, or racial
distribution. On multivariate analysis, anti-HBc status
and prior intravenous drug abuse remained signifi-
cantly associated with occult HBV liver (P  0.024 and
P  0.023, respectively). The Model for End-Stage Liver
Disease score at the time of enrollment was signifi-
cantly higher among those with occult HBV liver (18.6
vs. 16.7, P  0.03).
Association With HCC
Occult HBV liver was strongly associated with the pres-
ence of explant-proven HCC. Of 22 patients with occult
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Figure 1. Prevalence of occult HBV—enrollment and fol-
low-up data. *All 13 patients who were serum HBV DNA posi-
tive at 8 weeks were explant HBV DNA positive, and all had
detectable serum HBV DNA at enrollment.
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pared to 8 of 22 (36%) without occult HBV liver (P 
0.04; odds ratio  3.1; confidence interval  2.1-5.4).
On multivariate analysis incorporating age, alcohol
abuse, and gender, only occult HBV remained signifi-
cant (P  0.05). Hepatic HBV DNA concentrations were
comparable in those with and without HCC (median:
2.78 vs. 2.82 log10 copies/cell; P  0.08)
Post-OLT Follow-Up
A total of 44 patients who survived more than 3 months
post-OLT were further analyzed to delineate the post-
OLT course of occult HBV. The median post-OLT fol-
low-up was 13.2 months (range 3-25 months).
Post-OLT Course of Occult HBV Liver
Of the 22 patients who had HBV DNA detectable in the
explanted liver, 13 had detectable serum HBV DNA at 8
weeks post-OLT (range 1.7-2.6 log10 copies/mL, me-
dian 2.1 log10 copies/ mL), all of whom had detectable
serum HBV DNA pre-OLT. A total of 7 patients had HBV
detectable at 24 weeks post-OLT (range 2.2-3.3 log10
copies/mL, median 2.2 log10 copies/mL). Interestingly,
2 patients who had detectable serum HBV DNA at 24
weeks post-OLT did not have detectable HBV DNA in
the explant liver, and had undetectable serum HBV
DNA at week 8 post-OLT. Their serological correlates
are illustrated in Table 2.
No detectable HBsAg was noted at 8 or 24 weeks in
any of the patients tested, and all patients tested neg-
ative for HBsAg by immunostains on post-OLT liver
biopsy specimens (n  46). A total of 6 (32%) of those
with occult HBV liver suffered at least 1 episode of acute
cellular rejection (ACR), compared to 2 patients (8%)
without explant HBV DNA (P 0.04). All rejection epi-
sodes with a rejection activity index 6 were treated
with a modified steroid regimen (n  4). Refractory
rejection episodes requiring the use of thymoglobulin or
monoclonal antibodies were not noted.
Of the 22 patients with occult HBV liver, 1 of 13 with
TABLE 1. Comparison of Patients With and Without Occult HBV (Liver)
Variables
Occult HBV
(liver) (n  22) SD
No occult
HBV(liver) (n  22) SD P value
Mean age at enrollment (yr) 53.1 5.2 52.8 6.2 NS





MELD at enrollment 18.6 9.5 16.7 5.8 0.03
MELD at OLT 19.5 10.6 20.6 7.9 0.8
IVDA (%) 72 56 0.03
Anti-HBc positive (%) 12 (63) 6 (24) 0.01
Anti-HBs positive (%) 7 (36) 8 (32) 0.6
ACR (%) 6 (32) 2 (8) 0.04
HCC (%) 12 (63) 8 (32) 0.02
Recurrent HCV (%) 12 (54) 12 (54) 0.9
Abbreviations: AA, African-American; MELD, Model for End-Stage Liver Disease; IVDA, intravenous drug abuse; ACR, acute
cellular rejection; HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation.
TABLE 2. Hepatitis B Core and Surface Antibody in Relation to Detectable HBV DNA in Serum/Explant Liver
Anti-HBc Anti-HBc
Total n (%) Anti-HBs n Anti-HBs n Total n (%) Anti-HBs n Anti-HBs n
Enrollment (n  56) 27 29
Serum HBV DNA (n  16) 10/27 (37) 4 6 6/29 (21) 1 5
Serum HBV DNA (n  40) 17/27 (63) 12 5 23/29 (79) 8 15
OLT (n  44) 18 26
Liver HBV DNA (n  22) 13/18 (72) 6 7 9/26 (35) 1 8
Liver HBV DNA (n  22) 5/18 (28) 2 3 17/26 (65) 6 11
8 weeks post-OLT (n  44) 18 26
Serum HBV DNA (n  10) 6/18 (33) 4 2 4/26 (15) 2 2
Serum HBV DNA (n  34) 12/18 (67) 5 7 22/26(85) 4 18
24 weeks post-OLT (n  42) 16 26
Serum HBV DNA (n  7) 3/16 (19) 1 2 4/26 (15) 1 3
Serum HBV DNA (n  35) 13/16 (81) 6 7 22/26 (85) 4 18
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and 1 of 9 patients without detectable serum HBV DNA
at week 8 received a steroid pulse for ACR. Among the
22 patients without occult HBV liver, 1 of 2 patients
who manifested serum HBV DNA at 24 weeks and 1
patient who had undetectable serum HBV DNA at week
8 and 24 received a steroid pulse for ACR. No associa-
tion could be noted between post-OLT appearance of
serum HBV DNA and immunosuppressant regimen/
steroid pulses.
Serological Correlates
The presence of occult HBV correlated highly with the
anti-HBc status. Of 16 patients with detectable serum
HBV DNA at enrollment, 10 (63%) were positive for
anti-HBc, whereas only 17 (42%) out of the 40 patients
without serum HBV DNA tested positive for anti-HBc
(P  0.04). There was no significant difference in HBV
DNA concentrations in those with and without anti-
HBc (mean 1.8 [standard deviation 0.3] log10 cop-
ies/mL vs. 1.9 [standard deviation 0.3] log10 copies/
mL, respectively; P value not significant). Similarly, of
the 22 patients who had detectable hepatic HBV DNA,
13 (59%) were positive for anti-HBc (7 were negative for
anti-HBs) compared to 4 of 22 patients (18%) with un-
detectable explant HBV DNA (P  0.03). Again, no dif-
ference in hepatic HBV DNA concentration was noted in
those who were anti-HBc positive vs. those who were
anti-HBc negative (2.55 and 2.78 log10 copies/cell,
respectively; P value not significant). Interestingly, 7
patients with detectable explant HBV DNA were nega-
tive for all markers of prior HBV infection.
Conversely, 37% of those who were anti-HBc positive
had detectable serum HBV DNA at enrollment, com-
pared to 21% of those who were anti-HBc negative (P 
0.05). Similarly, 72% of anti-HBc positive patients had
detectable hepatic HBV DNA, compared to 35% of those
who were anti-HBc negative. This detailed serological
data is illustrated in Table 1.
Recurrence Rates of HCV
Liver biopsies were not performed on a protocol basis
but were prompted by abnormal liver-associated en-
zymes. With this approach, an overall histological re-
currence rate of 54% was noted. The median time in-
terval between OLT and the first documented
recurrence was 7.3 months (2.2 to 14.1 months). The
recurrence rate was 12 of 22 (54%) in patients with and
12 of 22 (54%) in those without occult HBV liver (P 
not significant). There were no significant differences in
the duration of follow-up and the mean number of liver
biopsies performed between the 2 groups. By multivar-
iate regression analysis, recurrent HCV was associated
with HCV viral load (pre-OLT RNA 850,000 IU/L),
ACR, and donor age 60 yr. It did not correlate with the
presence of occult HBV liver. This data is summarized
in Table 1.
Post-OLT Outcomes
A total of 5 patients died during their follow-up at a
median of 13.25 months from transplantation. A total
of 2 deaths occurred in patients with no evidence of
occult HBV liver—both attributed to overwhelming sep-
sis at 92 days and 13 months, respectively, post-OLT. A
total of 3 deaths occurred in patients with occult HBV
liver; 1 from fibrosing cholestatic hepatitis C occurring
20 months post-OLT and 6 months following treatment
of biopsy-proven ACR, 1 due to recurrent HCC 16
months from OLT, and 1 due to sepsis at 22 weeks
post-OLT. An additional patient with occult HBV liver
suffered recurrent fibrosing cholestatic hepatitis C and
was retransplanted at 8 months from the time of initial
OLT, and 7 months following initial documentation of
histological recurrence. Using Kaplan-Meier survival
analyses, no difference in survival was noted. One-year
patient survival rates were 94.8% in the occult HBV
liver group vs. 95% in the non-occult HBV liver group
(P  not significant).
DISCUSSION
The prevalence of occult HBV has been reported to vary
depending on the exposure of the overall population to
HBV, as well as the severity of liver disease, being
higher in patients with cirrhosis and HCC. As such, its
prevalence differs widely—a study from Japan demon-
strated a 75% prevalence in HCV-infected patients with
significant liver disease,15 while a similarly conducted
study from France showed a 5.5% prevalence.16 In the
United States, occult HBV infection is reported in 0 to
9% of the blood donor population, as compared to 7 to
19% in endemic areas.17,18 There is a paucity of North
American data examining occult HBV in patients with
chronic liver disease. A Canadian study demonstrated
its prevalence in 7 of 36 or 19.5% of those with unde-
fined chronic liver disease.19 Another study of a Cana-
dian hemodialysis population found that 3.8% of 239
HBsAg-negative patients were HBV DNA positive. Viral
loads in these individuals were low (102-104 viral cop-
ies/mL), and 78% of those tested had a mutation in the
HBV surface gene (sG145R mutant) that may lead to
false-positive results in some serologic assays for HB-
sAg. Demographic, biochemical, and HBV serological
testing did not help to identify those with occult HBV.20
Our study is the first to systematically examine the
prevalence rate and course of occult HBV in a U.S.
population with end-stage HCV undergoing OLT, utiliz-
ing a highly sensitive real-time polymerase chain reac-
tion assay. The 50% prevalence rate of occult HBV on
explant liver analysis is far higher than would be ex-
pected in an area of low endemicity, but may be ex-
plained by the fact that common risk factors predispose
to the acquisition of both viruses. Upon analysis of
these factors, intravenous drug abuse and positive an-
ti-HBc correlated with occult HBV. It should be noted
that all patients had very low concentrations of HBV
DNA. We found no evidence of overt HBV reactivation as
defined by appearance of serum HBsAg, an observation
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in keeping with a recent Italian study that examined the
significance of occult HBV in the post-OLT setting, as
well as an earlier retrospective analysis of stored
sera.21,22
One novel finding in our study was the appearance of
serum HBV DNA post-OLT. This occurred not only in
those with demonstrable HBV DNA in their explant
liver, but also in 2 patients without explant HBV DNA.
No definite correlation could be observed between ste-
roid pulses for ACR and this phenomenon of viral emer-
gence. There was no linear correlation noted between
pre-OLT serum HBV DNA or explant HBV DNA levels
with post-OLT serum HBV DNA. However, our results
may be limited by the relatively small numbers of pa-
tients in each group.
Occult HBV is often reported in the context of other
HBV serologies. Of the 22 patients with positive liver
HBV DNA described in our study, the majority (59%)
were anti-HBc positive, most of whom were negative for
anti-HBs. This is in keeping with earlier studies that
report the highest prevalence of occult HBV in anti-HBc
positive, anti-HBs negative individuals.2 Interestingly,
7 occult HBV liver patients (23%) had no markers of
prior HBV infection, a phenomenon that has also been
described.2 Plausible explanations for this phenome-
non involve mutations in the S gene, leading to false-
negative HBsAg test result, or in the preS region, and
downregulation of HBsAg expression.23
The molecular basis of HBV persistence in HBsAg
negative subjects is believed to involve a combination of
viral and host-dependent factors. One of the main char-
acteristics of these infections is the very low level of
circulating viral DNA and the low copy number per cell
of viral genomes in liver samples.22 This is confirmed in
our study, in which serum HBV DNA 3 log10 cop-
ies/mL pre- and post-OLT and explant liver HBV DNA
1.0 log10 copy/cell was observed in 0, 1, and 2
patients, respectively. Host-related factors are impor-
tant in immune clearance of HBV. Ample evidence now
exists that cytokines such as tumor necrosis factor 	
and interferon 
 play a major role in the posttranscrip-
tional downregulation and intracellular inactivation of
HBV genome expression. Synthesis of these cytokines
depends on HBV-specific cytotoxic T lymphocytes.24-26
In the post-OLT setting, the use of steroids and immu-
nosuppressants modifies the activity of these T-lym-
phocytes, and would theoretically cause reactivation of
the latent virus. However, the absence of de novo HBV
infection in our post-OLT population suggests that the
removal of the major reservoir of HBV (i.e., the host
liver) essentially eliminates the possibility of reactiva-
tion noted in the setting of other organ transplants.
In our study, the prevalence of occult HBV among
those with HCC was significantly higher than in those
without HCC. This data is consistent with epidemiolog-
ical and molecular studies, which implicate a possible
oncogenic role for occult HBV in the development of
HCC.27-30 The mechanisms whereby occult HBV infec-
tion contributes to hepatocellular transformation are
likely similar to that of overt HBV infection.28
In our study, histological HCV recurrence occurred at
a rate of approximately 50%, comparable to other stud-
ies.31 On multivariate analysis, HCV recurrence was
associated with at least 1 episode of ACR, pre-OLT viral
load 850,000 and donor age 60 yr. Occult HBV in-
fection was not a risk factor for recurrent HCV. This is
consistent with a retrospective analyses of stored sera
reported recently.32 It should be noted that protocol
liver biopsies were not performed at our center, but
were prompted by abnormal liver biochemistry. There-
fore, the possibility exists of having underestimated
HCV recurrence. Additionally, histological HCV recur-
rence may not have been an appropriate end-point—
perhaps progression or severity of recurrence would
have been a more useful indicator of outcome. Only a
small number of our patients had serial liver biopsies,
making analysis of histological progression difficult.
In summary, our prospective analysis found a high
prevalence of occult HBV in a U.S. transplant popula-
tion with end-stage HCV. All patients had low circulat-
ing and intrahepatic HBV DNA concentrations. The
presence of occult HBV is most reliably predicted by
positive anti-HBc/negative anti-HBs status of the sub-
ject. A strong association was noted between the pres-
ence of occult HBV and the development of HCC. De
novo cases of hepatitis B, defined as appearance of
serum HBsAg, were not detected. Although post-OLT
serum HBV DNA was transiently detected in some pa-
tients, at the present time anti-HBV therapy cannot be
recommended for this population. Larger studies will be
required to determine the true effect of occult HBV on
HCV recurrence post-OLT.
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